{"commentary":{"count":109,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":37,"podcast":36,"x_thread":35,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04466891\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"HERIZON-BTC-01","nct_id":"NCT04466891","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=herizon-btc-01-nct04466891. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"HERIZON-BTC-01","arms":[{"description":null,"label":"ZW25 (Zanidatamab) Monotherapy","type":"EXPERIMENTAL"}],"collaborators":["BeiGene","Jazz Pharmaceuticals Ireland Limited","BeOne Medicines LTD"],"completion_date":{"date":"2024-07-11","type":"ACTUAL"},"conditions":["HER2-amplified Biliary Tract Cancers"],"enrollment":{"count":87,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"ZW25 (Zanidatamab)","type":"DRUG"}],"last_update":"2025-09-15","lead_sponsor":"Jazz Pharmaceuticals","official_title":"A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-07-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)","timeFrame":"Up to 34 months"}],"references":[{"citation":"Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Lindsey S, Bachini M, Morement H, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer. Future Oncol. 2024;20(31):2319-2329. doi: 10.1080/14796694.2024.2368952. Epub 2024 Aug 8.","pmid":"39114870","type":"DERIVED"},{"citation":"Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2.","pmid":"37276871","type":"DERIVED"}],"start_date":{"date":"2020-10-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers","url":"https://clinicaltrials.gov/study/NCT04466891"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/herizon-btc-01-nct04466891"}